ArticleClinical pharmacology and therapeutics2013
Advancing the science of pharmacovigilance.
Article in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review.Pharmacoepidemiology and drug safety · 2023Pooled it
- Article
- Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Identifying Herbal Adverse Events From Spontaneous Reporting Systems Using Taxonomic Name Resolution Approach.Bioinformatics and biology insights · 2020Article
- Leveraging Food and Drug Administration Adverse Event Reports for the Automated Monitoring of Electronic Health Records in a Pediatric Hospital.Biomedical informatics insights · 2017Article
- A curated and standardized adverse drug event resource to accelerate drug safety research.Scientific data · 2016Article
- Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.PloS one · 2015Article
- Analyzing search behavior of healthcare professionals for drug safety surveillance.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2015Article
- A time-indexed reference standard of adverse drug reactions.Scientific data · 2014Article
- Text mining for adverse drug events: the promise, challenges, and state of the art.Drug safety · 2014Article
- Similarity-based modeling applied to signal detection in pharmacovigilance.CPT: pharmacometrics & systems pharmacology · 2014Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of detecting postmarketing safety signals earlier and with a high degree of fidelity is increasingly important and of great interest to industry, regulators, and the public. This issue of Clinical Pharmacology & Therapeutics contains two companion articles that represent exciting new advances in the field of pharmacovigilance and postmarketing safety signal detection. Given that drug safety evaluation and pharmacovigilance science are core competencies in the discipline of clinical pharmacology, these articles should be of interest to clinical pharmacologists as well as drug safety professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.